Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Possible one-dimensional 3He quantum fluid formed in nanopores.
Taniguchi J, Yamaguchi A, Ishimoto H, Ikegami H, Matsushita T, Wada N, Gatica SM, Cole MW, Ancilotto F, Inagaki S, Fukushima Y. Taniguchi J, et al. Among authors: matsushita t. Phys Rev Lett. 2005 Feb 18;94(6):065301. doi: 10.1103/PhysRevLett.94.065301. Epub 2005 Feb 14. Phys Rev Lett. 2005. PMID: 15783740
Superfluidity of 4He in one and three dimensions realized in nanopores.
Toda R, Hieda M, Matsushita T, Wada N, Taniguchi J, Ikegami H, Inagaki S, Fukushima Y. Toda R, et al. Among authors: matsushita t. Phys Rev Lett. 2007 Dec 21;99(25):255301. doi: 10.1103/PhysRevLett.99.255301. Epub 2007 Dec 19. Phys Rev Lett. 2007. PMID: 18233529
Improvement in gait velocity variability after cerebrospinal fluid elimination and its relationship to clinical symptoms in patients with idiopathic normal pressure hydrocephalus.
Yamamoto T, Fujito R, Chadani Y, Kashibayashi T, Kamimura N, Tsuda A, Akamatsu M, Matsushita T, Yamagami T, Ueba T, Saito M, Inoue K, Izumi M, Kazui H. Yamamoto T, et al. Among authors: matsushita t. Geriatr Gerontol Int. 2024 May 29. doi: 10.1111/ggi.14915. Online ahead of print. Geriatr Gerontol Int. 2024. PMID: 38810991
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
RECAP study group; Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Wakui H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. RECAP study group, et al. Among authors: matsushita t. Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15652. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38764356
2,212 results